Your browser doesn't support javascript.
Changes in anticancer treatment plans in patients with solid cancer hospitalized with COVID-19: analysis of the nationwide BSMO-COVID registry providing lessons for the future.
Geukens, T; Brandão, M; Laenen, A; Collignon, J; Van Marcke, C; Louviaux, I; Demey, W; Van Wambeke, S; Schrijvers, D; Lecomte, S; Mebis, J; Rutten, A; Fontaine, C; Lybaert, W; Aspeslagh, S; Goeminne, J-C; Van Den Bulck, H; Seront, E; De Backer, L; De Roock, W; Ignatiadis, M; Prenen, H; Van Beckhoven, D; Heijlen, M; Verheezen, J; Rottey, S; Punie, K; de Azambuja, E.
  • Geukens T; Laboratory for Translational Breast Cancer Research, KU Leuven, Leuven. Electronic address: tatjana.geukens@kuleuven.be.
  • Brandão M; Department of Medical Oncology, Institut Jules Bordet and L'Université Libre de Bruxelles (U.L.B), Brussels.
  • Laenen A; Leuven Biostatistics and Statistical Bioinformatics Centre (L-BioStat), KU Leuven, Leuven.
  • Collignon J; Department of Medical Oncology, CHU Liège, Liège.
  • Van Marcke C; Department of Medical Oncology, King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc, Brussels; Institut de Recherche Expérimentale et Clinique (IREC), Pole of Medical Imaging, Radiotherapy and Oncology (MIRO), Université Catholique de Louvain (UCLouvain), Brussels.
  • Louviaux I; Department of Medical Oncology, CHR Citadelle, Liège.
  • Demey W; Department of Medical Oncology, AZ Klina, Brasschaat.
  • Van Wambeke S; Department of Medical Oncology, Ziekenhuisnetwerk Antwerpen, Antwerp.
  • Schrijvers D; Department of Medical Oncology, Ziekenhuisnetwerk Antwerpen, Antwerp.
  • Lecomte S; Department of Medical Oncology, CHU Brugmann, Brussels.
  • Mebis J; Department of Medical Oncology, Jessa Hospital, Hasselt.
  • Rutten A; Department of Medical Oncology, Ziekenhuizen Gasthuiszusters Antwerp, Antwerp.
  • Fontaine C; Department of Medical Oncology, UZ Brussels, Brussels.
  • Lybaert W; Department of Medical Oncology, VITAZ, Sint-Niklaas.
  • Aspeslagh S; Department of Medical Oncology, UZ Brussels, Brussels.
  • Goeminne JC; Department of Medical Oncology, CHU-UCL Namur, Namur.
  • Van Den Bulck H; Department of Medical Oncology, Imelda Hospital, Bonheiden.
  • Seront E; Department of Medical Oncology, Hopital de Jolimont, Haine Saint Paul.
  • De Backer L; Department of Medical Oncology, Sint-Andriesziekenhuis, Tielt.
  • De Roock W; Department of Oncology-Hematology-Radiotherapy, Ziekenhuis Oost-Limburg and Limburgs Oncologisch Centrum, Genk.
  • Ignatiadis M; Department of Medical Oncology, Institut Jules Bordet and L'Université Libre de Bruxelles (U.L.B), Brussels; Academic Trials Promoting Team (ATPT), Institut Jules Bordet, Brussels.
  • Prenen H; Department of Oncology, University Hospital Antwerp, Edegem.
  • Van Beckhoven D; Department of Epidemiology and Public Health, Sciensano, Brussels.
  • Heijlen M; Department of General Medical Oncology and Multidisciplinary Breast Centre, Leuven Cancer Institute and University Hospitals Leuven, Leuven.
  • Verheezen J; Department of Medical Oncology, St. Trudo Hospital, Sint-Truiden.
  • Rottey S; Department of Medical Oncology, Ghent University Hospital, Ghent, Belgium.
  • Punie K; Department of General Medical Oncology and Multidisciplinary Breast Centre, Leuven Cancer Institute and University Hospitals Leuven, Leuven.
  • de Azambuja E; Department of Medical Oncology, Institut Jules Bordet and L'Université Libre de Bruxelles (U.L.B), Brussels.
ESMO Open ; 7(6): 100610, 2022 Nov 07.
Article in English | MEDLINE | ID: covidwho-2104895
ABSTRACT

BACKGROUND:

Solid cancer is an independent prognostic factor for poor outcome with COVID-19. As guidelines for patient management in that setting depend on retrospective efforts, we here present the first analyses of a nationwide database of patients with cancer hospitalized with COVID-19 in Belgium, with a focus on changes in anticancer treatment plans at the time of SARS-CoV-2 infection.

METHODS:

Nineteen Belgian hospitals identified all patients with a history of solid cancer hospitalized with COVID-19 between March 2020 and February 2021. Demographic, cancer-specific and COVID-specific data were pseudonymously entered into a central Belgian Society of Medical Oncology (BSMO)-COVID database. The association between survival and primary cancer type was analyzed through multivariate multinomial logistic regression. Group comparisons for categorical variables were carried out through a Chi-square test.

RESULTS:

A total of 928 patients were registered in the database; most of them were aged ≥70 years (61.0%) and with poor performance scores [57.2% Eastern Cooperative Oncology Group (ECOG) ≥2]. Thirty-day COVID-related mortality was 19.8%. In multivariate analysis, a trend was seen for higher mortality in patients with lung cancer (27.6% versus 20.8%, P = 0.062) and lower mortality for patients with breast cancer (13.0% versus 23.3%, P = 0.052) compared with other tumour types. Non-curative treatment was associated with higher 30-day COVID-related mortality rates compared with curative or no active treatment (25.8% versus 14.3% versus 21.9%, respectively, P < 0.001). In 33% of patients under active treatment, the therapeutic plan was changed due to COVID-19 diagnosis, most frequently involving delays/interruptions in systemic treatments (18.6%). Thirty-day COVID-related mortality was not significantly different between patients with and without treatment modifications (21.4% versus 20.5%).

CONCLUSION:

Interruption in anticancer treatments at the time of SARS-CoV-2 infection was not associated with a reduction in COVID-related mortality in our cohort of patients with solid cancer, highlighting that treatment continuation should be strived for, especially in the curative setting.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Observational study / Prognostic study Language: English Journal: ESMO Open Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Observational study / Prognostic study Language: English Journal: ESMO Open Year: 2022 Document Type: Article